Klaria Pharma Holding
0.81 SEK
+3.05 %
Less than 1K followers
KLAR
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Klaria Pharma Holding
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 4.2 | 5.9 | 2.3 | 9.0 | |||
| growth-% | 299.3 % | ||||||
| EBITDA | -11.0 | -35.3 | -39.1 | -43.9 | -14.7 | -31.2 | - |
| EBIT | -21.1 | -48.7 | -50.1 | -55.0 | -14.7 | -31.2 | -25.2 |
| Profit before taxes | -22.5 | -51.4 | -53.5 | -63.7 | -18.4 | -47.7 | -38.9 |
| Net income | -22.5 | -51.4 | -53.5 | -63.8 | -18.4 | -47.8 | -38.9 |
| EPS | -0.66 | -0.91 | -0.94 | -1.07 | -0.18 | -0.37 | -0.21 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -260.5 % | -748.6 % | -1,387.1 % | ||||
| EBIT-% | -499.5 % | -936.5 % | -1,387.1 % | -280.7 % | |||
| ROE | -27.4 % | -46.9 % | -77.1 % | -83.8 % | -44.7 % | -1,442.6 % | 1,002.5 % |
| ROI | -22.1 % | -38.8 % | -45.2 % | -53.0 % | -25.2 % | -83.4 % | -95.4 % |